Keratoconus Market

 Market Overview:

The 7 major keratoconus markets reached a value of US$ 202.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 275.0 Million by 2034, exhibiting a growth rate (CAGR) of 2.84% during 2024-2034.

The keratoconus market has been comprehensively analyzed in IMARC's new report titled "Keratoconus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Keratoconus is a progressive vision disorder in which the normally round, dome-shaped cornea gradually thins and weakens, causing it to bulge outwards into a cone shape. This abnormal form hinders light entering the eye from properly focusing on the light-sensitive retina, resulting in vision distortion. Keratoconus usually begins in the teenage years or early adulthood and can worsen over time, though the ailment's progression rate varies from person to person. The characteristic sign of keratoconus is the perception of several "ghost" images, called monocular polyopia. The other common symptoms associated with this condition include sensitivity to light and glare, eye strain or itching, blurry vision, nearsightedness, sudden clouding of vision, irregular astigmatism, etc. The diagnosis typically involves a review of the patient's medical history, visual indications, physical examination, and family history of ocular disease. The other tests and procedures to confirm the condition include slit lamp examination and retinoscopy. The healthcare professional may also perform a handheld keratoscopy, in which a series of concentric rings of light is projected onto the cornea to provide a simple, noninvasive visualization of the corneal surface.

The increasing prevalence of chronic eye inflammation caused by allergies and the rising incidence of connective tissue disorders, such as Ehlers-Danlos syndrome and Marfan syndrome, are primarily driving the keratoconus market. Apart from this, the growing cases of overexposure to the sun and ultraviolet radiation causing oxidative damage to the eye are also augmenting the market growth. Furthermore, the widespread adoption of efficient medications, including vitamin B2, omega-3 dietary supplements, artificial tears, etc., to moisten eyes and provide soothing relief to patients is creating a positive outlook for the market. Besides this, the inflating application of corneal topography for diagnosing the ailment, which demonstrates the cornea's thickness in various locations, along with the power, size, and shape of the anterior and posterior surfaces, is also bolstering the market growth. Moreover, numerous key players are making extensive investments in introducing disease-modifying treatments that target slowing the progression of the condition by strengthening the cornea and preventing it from becoming thinner. This, in turn, is acting as another significant growth-inducing factor. Additionally, the shifting preferences from penetrating keratoplasty towards nonpenetrating keratoplasty on account of its several associated benefits, including faster recovery time, lower risk of rejection, less post-operative astigmatism, etc., are expected to drive the keratoconus market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the keratoconus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for keratoconus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the keratoconus market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the keratoconus market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the keratoconus market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current keratoconus marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the keratoconus market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the keratoconus market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the keratoconus market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of keratoconus across the seven major markets?
• What is the number of prevalent cases (2018-2034) of keratoconus by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of keratoconus by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of keratoconus by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with keratoconus across the seven major markets?
• What is the size of the keratoconus patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of keratoconus?
• What will be the growth rate of patients across the seven major markets?
   

Keratoconus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for keratoconus drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the keratoconus market?
• What are the key regulatory events related to the keratoconus market?
• What is the structure of clinical trial landscape by status related to the keratoconus market?
• What is the structure of clinical trial landscape by phase related to the keratoconus market?
• What is the structure of clinical trial landscape by route of administration related to the keratoconus market?